Connect Biopharma Holdings (CNTB) Receivables - Net (2024 - 2025)

Connect Biopharma Holdings (CNTB) posted quarterly Receivables - Net of $13000.0 for Q4 2025, down 23.53% on a QoQ basis from $17000.0 in Q3 2025.

Connect Biopharma Holdings (CNTB) Receivables - Net (2024 - 2025) Analysis & Trends

Connect Biopharma Holdings (CNTB) has reported Receivables - Net for 2 consecutive years, with $13000.0 the latest figure, recorded in Q4 2025.

Quarterly Receivables - Net changed N/A year-over-year to $13000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13000.0 (changed N/A YoY) and the FY2025 annual result came in at $13000.0, down 98.35% from the prior year.
Receivables - Net slipped to $13000.0 in Q4 2025 per CNTB's latest filing, from $17000.0 in the prior quarter.
Over the last five years, Receivables - Net for CNTB reached as high as $3.6 million in Q2 2024 and fell as low as $8000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,981.90 Bn	66,981.62 Bn	-
2	Nanobiotix	1,913.50 Bn	1,913.44 Bn	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-
4	BeOne Medicines	472.03 Bn	467.24 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.09 Bn	114.84 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.01 Bn	61.26 Bn	3.31 Bn
7	Belite Bio	62.34 Bn	62.34 Bn	-
8	Argenx Se	55.99 Bn	50.80 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.49 Bn	34.48 Bn	959.66 Mn
10	Connect Biopharma Holdings	122.70 Mn	122.70 Mn	-

Download Data